Company · CIK 0001549595 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Nurix Therapeutics, Inc. · NRIX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 SForm 4 → | Sep 2, 7:42 pm EDT | Christine RingChief Legal Officer | 5,787 | $25.76 | $149,072 | 9,110 | −38.8% | 10b5-1 |
| Sep 2, 2026 MForm 4 → | Sep 2, 7:42 pm EDT | Christine RingChief Legal Officer | 5,787 | $8.72 | $50,463 | 14,897 | — | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 1, 5:19 pm EDT | Gwenn HansenChief Scientific Officer | 1,452 | $25.47 | $36,982 | 117,227 | −1.22% | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 1, 5:19 pm EDT | Gwenn HansenChief Scientific Officer | 1,452 | $1.86 | $2,701 | 118,679 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 MForm 4 → | Sep 2, 7:42 pm EDT | Christine RingChief Legal Officer | 5,787 | — | — | 117,037 | — | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 1, 5:19 pm EDT | Gwenn HansenChief Scientific Officer | 1,452 | — | — | 60,858 | — | 10b5-1 |